Balance Medical(SH:688198) Zheng Quan Zhi Xing·2025-06-13 09:41Core Viewpoint - The company announced the cancellation of certain unvested restricted stocks granted under the 2020 Restricted Stock Incentive Plan due to the departure of two incentive targets, resulting in a reduction of the number of incentive targets from 67 to 65 [8][9][11]. Group 1: Decision Process and Disclosure - The company followed the necessary decision-making procedures and disclosed information regarding the 2020 Restricted Stock Incentive Plan, including approvals from the board and independent directors [1][3][4]. - The independent directors provided their consent on various resolutions related to the incentive plan, ensuring compliance with relevant regulations [2][4][6]. Group 2: Specifics of the Canceled Restricted Stocks - A total of 0.7504 million shares of restricted stocks were canceled due to the departure of two incentive targets, which did not meet the eligibility criteria [9][11]. - The company achieved an operating income of 162.54 million yuan and a net profit of 162.54 million yuan, reaching 82.09% of the target value, which influenced the vesting ratio for the remaining incentive targets [9][10]. Group 3: Impact on the Company - The cancellation of the restricted stocks will not have a substantial impact on the company's financial status or operational results, nor will it affect the stability of the management team or the continuation of the stock incentive plan [13][14]. - The board's remuneration and assessment committee approved the cancellation, confirming compliance with legal and regulatory requirements [13][14]. Group 4: Legal Opinions - Legal opinions confirmed that the cancellation and adjustments made were in accordance with the relevant laws and regulations, and the actions taken were properly authorized [14][15].